HomeCompareBMY vs FIS

BMY vs FIS: Dividend Comparison 2026

BMY yields 4.17% · FIS yields 3.46%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BMY wins by $86.0K in total portfolio value
10 years
BMY
BMY
● Live price
4.17%
Share price
$59.73
Annual div
$2.49
5Y div CAGR
37%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$120.5K
Annual income
$39,823.66
Full BMY calculator →
FIS
FIS
● Live price
3.46%
Share price
$47.45
Annual div
$1.64
5Y div CAGR
16.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.5K
Annual income
$2,641.51
Full FIS calculator →

Portfolio growth — BMY vs FIS

📍 BMY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBMYFIS
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BMY + FIS cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BMY pays
FIS pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BMY
Annual income on $10K today (after 15% tax)
$354.34/yr
After 10yr DRIP, annual income (after tax)
$33,850.11/yr
FIS
Annual income on $10K today (after 15% tax)
$293.78/yr
After 10yr DRIP, annual income (after tax)
$2,245.28/yr
At 15% tax rate, BMY beats the other by $31,604.83/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BMY + FIS for your $10,000?

BMY: 50%FIS: 50%
100% FIS50/50100% BMY
Portfolio after 10yr
$77.5K
Annual income
$21,232.59/yr
Blended yield
27.40%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on FIS right now

BMY
Analyst Ratings
19
Buy
20
Hold
2
Sell
Consensus: Hold
Price Target
$62.73
+5.0% upside vs current
Range: $40.00 — $75.00
Altman Z
2.3
Piotroski
8/9
FIS
Analyst Ratings
1
Strong
21
Buy
14
Hold
1
Sell
Consensus: Buy
Price Target
$71.13
+49.9% upside vs current
Range: $54.00 — $85.00
Altman Z
0.2
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BMY buys
0
FIS buys
0
No recent congressional trades found for BMY or FIS in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBMYFIS
Forward yield4.17%3.46%
Annual dividend / share$2.49$1.64
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR37%16.8%
Portfolio after 10y$120.5K$34.5K
Annual income after 10y$39,823.66$2,641.51
Total dividends collected$91.0K$12.0K
Payment frequencyquarterlyquarterly
SectorHealthcareStock
Analyst consensusHoldBuy
Analyst price target$62.73$71.13

Year-by-year: BMY vs FIS ($10,000, DRIP)

YearBMY PortfolioBMY Income/yrFIS PortfolioFIS Income/yrGap
1← crossover$11,271$571.12$11,104$403.69+$167.00BMY
2$12,884$824.20$12,370$489.30+$514.00BMY
3$14,993$1,206.32$13,831$595.04+$1.2KBMY
4$17,839$1,797.27$15,526$726.25+$2.3KBMY
5$21,826$2,738.11$17,502$889.89+$4.3KBMY
6$27,643$4,289.31$19,823$1,095.07+$7.8KBMY
7$36,534$6,955.64$22,564$1,353.83+$14.0KBMY
8$50,861$11,770.13$25,826$1,682.21+$25.0KBMY
9$75,402$20,980.23$29,735$2,101.72+$45.7KBMY
10$120,504$39,823.66$34,458$2,641.51+$86.0KBMY

BMY vs FIS: Complete Analysis 2026

BMYHealthcare

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Full BMY Calculator →

FISStock

Fidelity National Information Services, Inc. provides technology solutions for merchants, banks, and capital markets firms worldwide. It operates through Merchant Solutions, Banking Solutions, and Capital Market Solutions segments. The Merchant Solutions segment offers enterprise acquiring, software-led small- to medium-sized businesses acquiring, and global e-commerce solutions. The Banking Solutions segment provides core processing and ancillary applications; digital solutions, including Internet, mobile, and e-banking; fraud, risk management, and compliance solutions; electronic funds transfer and network services; card and retail payment solutions; wealth and retirement solutions; and item processing and output services. The Capital Market Solutions segment offers securities processing and finance, global trading, asset management and insurance, and corporate liquidity solutions. Fidelity National Information Services, Inc. was founded in 1968 and is headquartered in Jacksonville, Florida.

Full FIS Calculator →
📬

Get this BMY vs FIS comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BMY vs SCHDBMY vs JEPIBMY vs OBMY vs KOBMY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.